The dissolution of TFF Pharmaceuticals is now in its final stages. Following the strategic decision to wind down operations, company leadership is focused on monetizing its core technology platform. For shareholders, the pivotal question remains whether any capital will be available for distribution after all creditor obligations are settled.
The company’s financial position is critical. In regulatory filings, TFF Pharmaceuticals has formally acknowledged “substantial doubt” regarding its ability to continue as a going concern. This declaration is a necessary step, as operational activities ceased by the end of 2024 and available cash is limited relative to outstanding liabilities.
The timeline for the final liquidation and settlement…